Studies On The Effects Of Ginkgo Biloba Extract In Drug-naive First-episode Schizophrenia

Schizophrenia is a serious mental disorder, since the etiology and pathogenesis is unknown.Recent research shows that schizophrenia pathogenesis is relative to free radicals. Extract of Ginkgo biloba(EGb761) is used in this trial,which includes many pharmacological effects,such as antioxidation, remove and inhibition of lipid peroxidation product, Antibacterial/antiviral activity, antiphlogosis, nerve damage protection, platelet active factor(PAF) antagonism, changing the blood rheology, vasodilatation,et al. So the study will be conducted on the basis of Ginkgo biloba extract having the activity captured the free radicals.Through being compared with placebo for clinical analysis, to explore the effects of Ginkgo biloba extract on plasma antioxidant enzymes system, Clinical symptoms and cognitive function in inpatients with first-episode schizophrenia.Therefore, clinical drug efficacy research that ginkgo biloba extract is applied to treat drug-naive first-episode schizophrenia has the research significance. There will still have a profound significance in the development of new effect of traditional Chinese medicine.To establish this grouping model that is about ginkgo biloba extract (EGb761) treating first-episode schizophrenia. The course of the treatment is 12 weeks. All cases were randomly divided into experimental group and control group. The experimental group took Ginkgo biloba extract and risperidone and the control group took placebo and risperidone. The efficacy was assessed with the Positive and Negative Symptoms Scale (PANSS) at baseline and after 4,8, 12-week treatment. The side effects was assessed with the Treatment Emergent Symptoms Scale (TESS) after 4,8,12-week treatment. Using Stroop Test and repeatable battery for the assessment of neuropsychological status (RBANS) to assess the cognitive function before the treatment and 12 weekends, respectively. The experimental group and control group were extracted peripheral blood with an empty belly in the early morning at baseline and 12 weekends, respectively. Making use of the kit that is producted by the Nanjing Jiancheng Science and technology limited company to detect the total SOD, CAT, GSH-Px activity and the MDA content in plasma.At the same period, selecting 79 healthy persons as the normal control group, which was taken peripheral blood before and after treatment to test the above-mentioned biochemical indicators in the same way. There was no significant difference between the three groups in sex ratio, course of disease, age and length of education (P>0.05).According to the statistics results, we know that the inpatient with first-episode schizophrenia are in the nature of oxidative stress state.Through ginkgo biloba extract (EGb761) treating 12 weeks, these inpatients' each index of antioxidant enzymes were improved obviously; Ginkgo biloba extract(EGB 761) added to risperidone can more effectively alleviate mental symptoms, improve cognitive function and reduce the side effects taken risperidone than placebo added to risperidone.So using Ginkgo biloba extract(EGB 761) to treat first-episode schizophrenia has the value of clinical applications.Innovative features:1. Selected patients are all patients with first-episode schizophrenia which did not take any antipsychotic drugs.So that can avoid drug effects. Large samples were collected, so it is more significantly convincing and improved the accuracy.2. For the first time, the traditional Chinese medicine-Ginkgo biloba extract was used to treat patients with first-episode schizophrenia, which would give a new way for the treatment of first-episode schizophrenia.3. For the first time to detect the biochemical indicators of SOD, GSH-Px, CAT three kinds of antioxidant enzymes activities and the MDA content in plasma of patients with first-episode schizophrenia in treatment with the Ginkgo biloba extract.4. For the first time, Two cognitive test tools-RBANS, Stroop were used to assess the therapeutic effect of the patients with first-episode schizophrenia existing a decline in cognitive function in treatment with the Ginkgo biloba extract.